Biotech · Public company · Doylestown, PA, US
Aprea Therapeutics, Inc.
Ticker APRE · SEC CIK 0001781983
Track this companyFree. Adds Aprea Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials112 recruiting or active
Pipeline programs16From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline16
- APR-246 + azacitidinePhase 3 · MDSClinicalTrials.gov · fetched Nov 12, 2026
- AzacitidinePhase 3 · MDSClinicalTrials.gov · fetched Nov 12, 2026
- APR-246Phase 2 · Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53ClinicalTrials.gov · fetched Nov 12, 2026
- APR-246Phase 2 · Acute Myeloid Leukemia or Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- APR-246 (eprenetapopt) + Acalabrutinib in CLLPhase 2 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- APR-246 (eprenetapopt) + PembrolizumabPhase 2 · Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RTPhase 2 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLLPhase 2 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RTPhase 2 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- ATRN-119Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)Phase 2 · Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53ClinicalTrials.gov · fetched Nov 12, 2026
- APR-1051Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- APR-246Phase 1 · Myeloid MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- APR-548 + AzacitidinePhase 1 · MDSClinicalTrials.gov · fetched Nov 12, 2026
- AzacitidinePhase 1 · Myeloid MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 1 · Myeloid MalignancyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDSPHASE1 · NOT_YET_RECRUITING · started Nov 30, 2026ClinicalTrials.gov NCT07617363 · fetched Nov 12, 2026
- Study of APR-1051 in Patients With Advanced Solid TumorsPHASE1 · RECRUITING · started Jun 13, 2024ClinicalTrials.gov NCT06260514 · fetched Nov 12, 2026
- Study Of ATRN-119 In Patients With Advanced Solid TumorsPHASE1_PHASE2 · COMPLETED · started Jan 9, 2023ClinicalTrials.gov NCT04905914 · fetched Nov 12, 2026
- APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)PHASE1 · TERMINATED · started Sep 20, 2021ClinicalTrials.gov NCT04638309 · fetched Nov 12, 2026
- APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)PHASE1_PHASE2 · TERMINATED · started Mar 2, 2021ClinicalTrials.gov NCT04419389 · fetched Nov 12, 2026
- Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor MalignanciesPHASE1_PHASE2 · COMPLETED · started Jun 25, 2020ClinicalTrials.gov NCT04383938 · fetched Nov 12, 2026
- APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid MalignanciesPHASE1 · COMPLETED · started Dec 13, 2019ClinicalTrials.gov NCT04214860 · fetched Nov 12, 2026
- APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell TransplantPHASE2 · COMPLETED · started Sep 16, 2019ClinicalTrials.gov NCT03931291 · fetched Nov 12, 2026
- APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)PHASE3 · COMPLETED · started Jan 11, 2019ClinicalTrials.gov NCT03745716 · fetched Nov 12, 2026
- Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid NeoplasmsPHASE1_PHASE2 · COMPLETED · started May 18, 2017ClinicalTrials.gov NCT03072043 · fetched Nov 12, 2026
- p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246PHASE1_PHASE2 · COMPLETED · started Mar 1, 2014ClinicalTrials.gov NCT02098343 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 28, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 23, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 17, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 1, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Mar 30, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 16, 2026 · fetched Nov 12, 2026
NIH awards1
- Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancerFiscal year 2024 · $1.1MNIH RePORTER 5R44CA278078-02 · fetched Nov 12, 2026